Healthcare Private Placement and M&A Transactions Review Week Ending September 17, 2023

Generate Biomedicines: The company raised $273 million of Series C venture funding from Amgen, nVentures and Maps Capital on September 14, 2023. Altitude Life Science Ventures, ARCH Venture Partners, Fidelity Management & Research, Morningside Group, Flagship Pioneering, March Capital, Partners Investment, Abu Dhabi Investment Authority, Alaska Permanent Fund, T. Rowe Price and Pictet Alternative Advisors also participated in the round. The company is a developer of a generative biology platform designed to invent new drugs across protein modalities and protein therapeutics.

ROME Therapeutics: The company raised $149 million of Series B venture funding from GV, Alexandria Venture Investments and Johnson & Johnson Innovation – JJDC on September 12, 2023. Bristol-Myers Squibb, Sanofi Ventures, Raycap, Andreessen Horowitz, Eurofarma Ventures, Luma Group, S32, ARCH Venture Partners, Mass General Brigham Ventures, Mirae Asset Capital, Sigmas Group and Casdin Capital also participated in the round. The company is a developer of novel therapies intended to cure cancer and autoimmune diseases.

DalCor Pharmaceuticals: The company raised $80 million of Series D venture funding from Investissement Québec, Fonds de solidarité FTQ and CTI Life Sciences Fund on September 13, 2023. Fonds de Developpement Économique, Andes Growth and TB Pharma also participated in the round. The company is a developer of medicinal drugs intended to facilitate the efficient treatment of cardiovascular diseases.

Actio Biosciences: The company raised $55 million of Series A venture funding in a deal led by Droia Ventures and Canaan Partners on September 12, 2023. EcoR1 Capital, Deerfield Management and Euclidean Capital also participated in the round. The company is a developer of a portfolio of drugs intended to cure rare diseases that could also help treat common illnesses.

restor3d: The company raised $29 million of venture funding from undisclosed investors on September 12, 2023. The company is a developer of 3D-printed implant technology designed to repair and reconstruct the human body.

Conjupro Biotherapeutics: The company raised $9.3 million of venture funding from undisclosed investors on September 13, 2023. The company is an operator of a biopharmaceutical company intended to focus on clinical research and drug development for treating oncology, cardiology and CNS diseases.

Navigation Sciences: The company closed on $3 million of a $5 million targeted amount of Series B venture funding on September 14, 2023. The company is a developer of image-guided surgery technology intended to improve surgical recurrence risk outcomes and increase operational efficiency.

Balto Pharmaceuticals: The company raised $2 million of venture funding from undisclosed investors on September 13, 2023. The company is an operator of a drug discovery platform intended to regenerate protein interactions (PPIs) in cancer and other diseases.

Lumen Bioscience: The company is in the process of raising venture funding on September 15, 2023. The company is an operator of a biosciences company intended to develop biologic drugs faster than traditional methods.

Dianthus Therapeutics / Magenta Therapeutics: The company acquired Magenta Therapeutics through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol DNTH on September 11, 2023. Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies.

Calidi Biotherapeutics / First Light Acquisition Group: The company went Public Company through a reverse merger, resulting in the combined entity trading on the New York Stock Exchange under the ticker symbol ”CLDI” on September 12, 2023. Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Resolution Bioscience / Exact Sciences: The company, a subsidiary of Agilent Technologies, reached a definitive agreement to be acquired by Exact Sciences for an undisclosed amount on September 12, 2023. The company is a developer of novel biochemistry and bioinformatics technologies designed to enhance the capabilities of DNA sequencing platforms.